Cancer Drug Design and Discovery
Editat de Stephen Neidleen Limba Engleză Hardback – 4 dec 2013
- Provides a clinical perspective on the development of new molecularly targeted anticancer agents with the latest and most promising chemotherapeutic approaches
- Offers a broad view of where the field is going, what tools drug discovery is using to produce new agents and how they are evaluated in the laboratory and clinic
- Features 6 new chapters devoted to advances in technology and successful anticancer therapies, such as cancer genomics and personalized medicine, DNA-targeted agents, B-Raf inhibitors and more
- Each chapter includes extensive references to the primary and review literature, as well as to relevant web-based sources
Preț: 598.03 lei
Preț vechi: 790.63 lei
-24% Nou
Puncte Express: 897
Preț estimativ în valută:
114.44€ • 120.36$ • 95.62£
114.44€ • 120.36$ • 95.62£
Carte tipărită la comandă
Livrare economică 01-15 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780123965219
ISBN-10: 0123965217
Pagini: 640
Ilustrații: 50 illustrations
Dimensiuni: 191 x 235 x 43 mm
Ediția:Revised
Editura: ELSEVIER SCIENCE
ISBN-10: 0123965217
Pagini: 640
Ilustrații: 50 illustrations
Dimensiuni: 191 x 235 x 43 mm
Ediția:Revised
Editura: ELSEVIER SCIENCE
Public țintă
Translational researchers and clinicians interested in modern drug discovery, cancer biology and medicine, as well as graduate and undergraduate students in pharmacy, pharmacology or medicinal and biological chemistry.Cuprins
Introduction - Stephen Neidle
Foreword - Hilary Calvert
Part I. Basic Principles and methodology
Modern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman and Ian Collins
Pharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo and Federico Innocenti
Structural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi and Harren Jhoti
Part II. Drugs in the laboratory and clinic
Temozolomide: from cytotoxic to molecularly-targeted agent — Malcolm Stevens
Temozolomide: patents and the perils of invention — Malcolm Stevens
A new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaud and Christian Bailly
Inhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G Generali
The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and Rolf W. Hartmann
Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H Siddik
Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agents — Ian R Hardcastle
Targeting altered metabolism – emerging cancer therapeutic strategy — Minsuh Seo, Robert Blake Crochet and Yong-Hwan Lee
Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W. Rewcastle
Antibody-drug conjugates delivering DNA cytotoxics — John A Hartley
Inhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B. Cohen and Tracy M. Bryan
Targeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A Harris
Part III. The reality of cancer drugs in the clinic
Failure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren and Christopher. A. Slapak
Anticancer drug registration and regulation: current challenges and possible solutions — David Taylor, Erling Donnelly and Silvia Chioato
Foreword - Hilary Calvert
Part I. Basic Principles and methodology
Modern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman and Ian Collins
Pharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo and Federico Innocenti
Structural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi and Harren Jhoti
Part II. Drugs in the laboratory and clinic
Temozolomide: from cytotoxic to molecularly-targeted agent — Malcolm Stevens
Temozolomide: patents and the perils of invention — Malcolm Stevens
A new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaud and Christian Bailly
Inhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G Generali
The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and Rolf W. Hartmann
Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H Siddik
Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agents — Ian R Hardcastle
Targeting altered metabolism – emerging cancer therapeutic strategy — Minsuh Seo, Robert Blake Crochet and Yong-Hwan Lee
Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W. Rewcastle
Antibody-drug conjugates delivering DNA cytotoxics — John A Hartley
Inhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B. Cohen and Tracy M. Bryan
Targeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A Harris
Part III. The reality of cancer drugs in the clinic
Failure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren and Christopher. A. Slapak
Anticancer drug registration and regulation: current challenges and possible solutions — David Taylor, Erling Donnelly and Silvia Chioato
Recenzii
"…offers unique information on the discovery and design of new anticancer agents, covering recent notable successes resulting from the human genome and cancer genomics projects…an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry…" --Anticancer Research 34, 2014
"The second edition of this book walks readers through the myriad cancer drugs and their molecular targets, with a special emphasis on past, present, and future drug design efforts... the book examines both drugs currently in the clinic and those merely on the drawing board…This comprehensive update of the 2008 edition will serve student or experienced cancer researchers well as a reference on anticancer drug development." Rating: 4 Stars --Doody.com, March 21, 2014
"Specialists in cancer and pharmaceuticals, most in academic settings, look at basic principles of cancer drugs, methodology, drugs in the clinic, new agents, and the reality of cancer drugs in the clinic…They do include many case studies, and some chapters provide questions for classroom use." --ProtoView.com, February 2014
"The second edition of this book walks readers through the myriad cancer drugs and their molecular targets, with a special emphasis on past, present, and future drug design efforts... the book examines both drugs currently in the clinic and those merely on the drawing board…This comprehensive update of the 2008 edition will serve student or experienced cancer researchers well as a reference on anticancer drug development." Rating: 4 Stars --Doody.com, March 21, 2014
"Specialists in cancer and pharmaceuticals, most in academic settings, look at basic principles of cancer drugs, methodology, drugs in the clinic, new agents, and the reality of cancer drugs in the clinic…They do include many case studies, and some chapters provide questions for classroom use." --ProtoView.com, February 2014